RxDoctor Payments Data

Dmitriy Kosyagin, MD

Internal Medicine · Las Vegas, NVNPI 1427020759

Payments from drug & device makers

$530in general payments, 2019–2025

Across 34 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$126
  • Boehringer Ingelheim$107
  • Pfizer$64
  • Merck$60
  • Novo Nordisk$59
  • Biohaven Pharmaceutical Holding Company Ltd.$27
  • plus $88 from 6 others

What the payments were for

  • Food & beverage$530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$530 in reported general payments places this provider in the 60th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$13,942
Medicare patients
85
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$125,360
JardianceEmpagliflozin79$82,039
OzempicSemaglutide43$49,228
MounjaroTirzepatide42$47,749
TrulicityDulaglutide40$38,509
FarxigaDapagliflozin Propanediol34$28,106
XareltoRivaroxaban16$25,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$22,709
JanuviaSitagliptin Phosphate13$20,851
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$16,939
Humalog Kwikpen U-100Insulin Lispro22$8,775
Spiriva RespimatTiotropium Bromide12$8,675
SymbicortBudesonide/Formoterol Fumarate15$8,386
Arnuity ElliptaFluticasone Furoate17$7,742
Atorvastatin Calcium926$7,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$125,360168 claims
Boehringer IngelheimJardiance, Spiriva Respimat$107$90,71491 claims
Novo NordiskOzempic$59$49,22843 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$126$47,39071 claims
Johnson & JohnsonXarelto$12$25,24216 claims
MerckJanuvia$60$20,85113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →